Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | KCNA5 | P22460 | 5/20 | 0.40 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5429300 | 0.78 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3SMN1; SMN2MEN1 | |
| SCHEMBL2937192 | 0.78 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3SMN1; SMN2MEN1 | |
| Bromide SCHEMBL10445117 | 0.78 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3SMN1; SMN2MEN1 | |
| SCHEMBL702161 | 0.75 | SMN1; SMN2 (0.49) | SLC6A2SLC6A4SLC6A3SMN1; SMN2MEN1 | |
| SCHEMBL5032376 | 0.75 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3SMN1; SMN2MEN1 | |
| SCHEMBL3628303 | 0.75 | SMN1; SMN2 (0.49) | SLC6A2SLC6A4SLC6A3SMN1; SMN2MEN1 | |
| SCHEMBL29700907 | 0.75 | SMN1; SMN2 (0.49) | SLC6A2SLC6A4SLC6A3SMN1; SMN2MEN1 | |
| SCHEMBL5581899 | 0.75 | SMN1; SMN2 (0.49) | SLC6A2SLC6A4SLC6A3SMN1; SMN2MEN1 | |
| SCHEMBL22275828 | 0.75 | SMN1; SMN2 (0.49) | SLC6A2SLC6A4SLC6A3SMN1; SMN2MEN1 | |
| SCHEMBL29914092 | 0.75 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4121421-B1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | NOVARTIS AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| CN-119241481-A | Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors | 诺华股份有限公司 | 2025-01-03 | — | — | CN | disclosed |
| US-20240382457-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | NOVARTIS PHARMA AG (CH) | 2024-11-21 | — | — | US | disclosed |
| CN-115298170-B | Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors | 诺华股份有限公司 | 2024-09-27 | — | — | CN | disclosed |
| US-12083101-B2 | Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors | NOVARTIS AG (CH) | 2024-09-10 | — | — | US | disclosed |
| EP-4121421-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | Novartis AG (CH) | 2023-01-25 | — | — | EP | disclosed |
| CN-115298170-A | Biaryl derivatives as inhibitors of YAP/TAZ-TEAD protein-protein interactions | 诺华股份有限公司 | 2022-11-04 | — | — | CN | disclosed |
| US-20210299100-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | NOVARTIS PHARMA AG (CH) | 2021-09-30 | — | — | US | disclosed |
| WO-2021186324-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | NOVARTIS AG (CH) | 2021-09-23 | — | — | WO | disclosed |
| EP-0883622-B1 | PROTON PUMP INHIBITOR | APOTEX INC (CA) | 2002-05-15 | — | — | EP | disclosed |
| US-6114537-A | 1,2,4-THIADIAZOLE COMPOUND IS USEFUL FOR TRAPPING THIOL COMPOUNDS AND SELECTIVELY CHANGING THIOLS TO DISULFIDE COMPOUNDS | APOTEX INC. (CA) | 2000-09-05 | — | — | US | disclosed |
| US-6093738-A | IMIDAZO(1,2-D)-THIADIAZOLE COMPOUNDS; PEPTIC ULCER TREATMENT | KARIMIAN KHASHAYAR (CA) | 2000-07-25 | — | — | US | disclosed |
| EP-0883622-A1 | PROTON PUMP INHIBITOR | APOTEX INC. (CA) | 1998-12-16 | — | — | EP | disclosed |
| EP-0883606-A1 | PROCESS FOR SCAVENGING THIOLS | APOTEX INC. (CA) | 1998-12-16 | — | — | EP | disclosed |
| US-5677302-A | Thiadiazole compounds useful as proton pump inhibitors | APOTEX INC. (CA) | 1997-10-14 | — | — | US | disclosed |
| WO-1997031923-A1 | PROTON PUMP INHIBITOR | APOTEX INC. (CA) | 1997-09-04 | — | — | WO | disclosed |
| WO-1997031893-A1 | PROCESS FOR SCAVENGING THIOLS | APOTEX INC. (CA) | 1997-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12083101-B2 | Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors | YAP1, TEAD3, TEAD2 | TRPA1 4084/4885SLC6A2 3628/4885SLC6A4 4459/4885 |
| US-20240382457-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | YAP1, TEAD3, TEAD2 | TRPA1 4084/4885SLC6A2 3628/4885SLC6A4 4459/4885 |
| US-20210299100-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | YAP1, TEAD3, TEAD2 | TRPA1 4155/4885SLC6A2 3704/4885SLC6A4 4472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.